Ranjit Banwait, MD, M.Sc

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: nej.md/4mh5RPL @ASCO

Celebrating the Class of 2025 Hematology/Oncology fellows last night! Congratulations! We are so proud of all your hard work and accomplishments @mayscancer @UTHSAResearch @HemOncFellows @ranjitbanwait @AggieMD @DrSAHaddad @mazo_md

Excited to share our work published today. Shout out to @VKaklamani for her amazing mentorship! @UTHealthSAMDA Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors - onlinelibrary.wiley.com/doi/10.1002/ij…

Our cancer survivorship walk/run. Fellowship program represented @LSOM_HemOnc @UTHealthSAMDA

I just registered for Give Cancer the Boot Survivorship 5K and 1-Mile Walk. Why don't you join me? 🏃‍♂️🏃‍♂️🏃‍♂️ athleteguild.com/event/san-anto…

The history of #SABCS reviewed by @VKaklamani. The first symposium was held in 1978, with 30 attendees and talks by Drs Fisher and Lippman. #SGBCC2025

Please consider registering ⁦@_MDEducation⁩

Great #sabcssnippet on approval of datodxd. @hoperugo @KateIdaLathrop @SABCSSanAntonio @UTHealthSAMDA @AACR youtube.com/watch?v=J-4Gc6…

Simultaneous @NatureMedicine pub of 2 neoadjuvant chemo-IO trials for high-risk ER+ BC: KN-756 & CM-7FL. Both found a striking improvement in pCR rate with IO, with larger Δ if PD-L1+ or low ER. Waiting for EFS data, which will most likely impact practice. nature.com/articles/s4159…

Money slide💰: Snapshot of survival data for all 1st line CDK4i trials in advanced breast cancer

FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer fda.gov/drugs/resource… #OCENewsBurst

Setting up for #sabcs24 underway. To all who are traveling to San Antonio safe travels.@SABCSSanAntonio @AACR @UTHealthSAMDA

Busy but exciting morning presenting our study on Phase II trial w/ Lenvatinib + Eribulin combo in advanced solid tumors at #ASCO24 Shout out to @VKaklamani @LSOM_HemOnc @UTHealthSAMDA for the support!

Registration for the #SIOG2024 Annual Conference is NOW open! Reserve your spot to meet in Montreal, Canada, on 17-19 October. The deadline for Early Registration is 22 August. #GeriOnc Register NOW! loom.ly/-5tvm6U

EVE trial update: secondary VTE prevention in cancer patients. Lower dose of apixaban 2.5mg vs 5mg did not lower combined bleeding event. Similar recurrent VTE or arterial thrombosis rates in both groups. Led by our faculty, Dr. Usha Perepu! jthjournal.org/article/S1538-…

Ecstatic to have received @ASCO @ConquerCancerFd Merit Award for our poster abstract at #ASCO24. Grateful for amazing mentorship from @VKaklamani @DrSukeshiArora @mazo_md and Dr. Kate Lathrop @UTHealthSAMDA

2023 was an outstanding year for breast cancer research As we start wrapping up #SABCS23, we need to think about how to incorporate what we learned in the clinic and future research. Looking forward to what is yet to come to improve outcomes for our patients! @OncoAlert #BCSM

Love this PREFERABLE-EFFECT study by Netherlands group at #SABCS23 showing decreased fatigue and increased QOL with structured exercise program in advanced breast cancer pts. Does it have a role in endocrine resistance? @VKaklamani @mazo_md

Just walked over to the convention center. Everything is getting ready for #sabcs23. Weather sunny and in the 60s. Excited about all the science. @SABCSSanAntonio @AACR @CarlosArteagaMD @hoperugo @DrWGradishar @dradityabardia @matteolambe @OncoAlert

Awesome time at #SIOG2023. Thanks to @DrSukeshiArora for her mentorship and scientific committee @SIOGorg @YoungSIOG for allowing us to showcase the important work being done @UTHealthSAMDA for the betterment of older cancer patient. Intrigued and excited for #SIOG2024 @Montreal